- PA5-28162 - Invitrogen Antibodies RGS2 antibody

Submitted references Single-Cell RNA-Sequencing Reveals Lineage-Specific Regulatory Changes of Fibroblasts and Vascular Endothelial Cells in Keloids.

Liu X, Chen W, Zeng Q, Ma B, Li Z, Meng T, Chen J, Yu N, Zhou Z, Long X
The Journal of investigative dermatology 2022 Jan;142(1):124-135.e11

ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21.

Deng M, Wei W, Duan J, Chen R, Wang N, He L, Peng Y, Ma X, Wu Z, Liu J, Li Z, Zhang Z, Jiang L, Zhou F, Xie D
Cancer science 2021 May;112(5):1758-1771

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using RGS2 Polyclonal Antibody (Product # PA5-28162). Sample (30 µg whole cell lysate). A: H1299. 12% SDS PAGE. RGS2 Polyclonal Antibody (Product # PA5-28162) diluted at 1:1,000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: RGS2 Polyclonal Antibody detects RGS2 protein by Western blot analysis. A. 30 µg Neuro2A whole cell lysate/extract.12 % SDS-PAGE. RGS2 Polyclonal Antibody (Product # PA5-28162) dilution: 1:1,000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of RGS2 in methanol-fixed A549 cells using a RGS2 polyclonal antibody (Product # PA5-28162) at a 1:200 dilution.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry (Paraffin) analysis of RGS2 was performed in paraffin-embedded rat ovary tissue using RGS2 Polyclonal Antibody (Product # PA5-28162) at a dilution of 1:500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 7 FIGURE Low ZHX3 expression combined with high RGS2 expression predicts the best prognosis of patients with UCB. A, High expression of ZHX3 and low expression of RGS2 were examined by IHC in 1 UCB case (top), and low expression of ZHX3 and overexpression of RGS2 were examined by IHC in another UCB case (below). The correlation between the expression levels of ZHX3 and RGS2 was evaluated in 199 UCB tissues, and the results showed that ZHX3 expression levels are negatively correlated with RGS2. * P < .05. B, C, Further Kaplan-Meier analysis revealed that patients with both low ZHX3 and high RGS2 expression had the best survival rate in the SYSUCC cohort ( P < .0001). D, Graphical representation reveals a proposed model for the role and major mechanism of the ZHX3/RGS2/RhoA signaling pathway in regulating the progression of UCB cells

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 7 Low ZHX3 expression combined with high RGS2 expression predicts the best prognosis of patients with UCB. A, High expression of ZHX3 and low expression of RGS2 were examined by IHC in 1 UCB case (top), and low expression of ZHX3 and overexpression of RGS2 were examined by IHC in another UCB case (below). The correlation between the expression levels of ZHX3 and RGS2 was evaluated in 199 UCB tissues, and the results showed that ZHX3 expression levels are negatively correlated with RGS2. * P < .05. B, C, Further Kaplan-Meier analysis revealed that patients with both low ZHX3 and high RGS2 expression had the best survival rate in the SYSUCC cohort ( P < .0001). D, Graphical representation reveals a proposed model for the role and major mechanism of the ZHX3/RGS2/RhoA signaling pathway in regulating the progression of UCB cells

PA5-28162

Antibody data